<DOC>
	<DOC>NCT02029586</DOC>
	<brief_summary>This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.</brief_summary>
	<brief_title>Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>NAFLD Activity Score(NAS) ≥ 3 (Biopsyproven) Alcohol consumption &gt; 20g/day Type 1 diabetes or poorly controlled diabetes mellitus (HbA1c ≥ 9%) Evidence of other chronic liver disease (e.g. HBsAg positive, antiHCV positive, autoimmune hepatitis, Wilson's disease, alpha1 antitrypsin deficiency and etc.) ALT, AST &gt; 5X the upper limit of normal Serum creatinine ≥ 2mg/dl Fibrosis score ≥ 3 according to the NASH CRN fibrosis staging system NQO1 T/T type Weight loss of more than 5kg within 6 months Bariatric surgery within 6 months Known alcohol or any other drug abuse in the last five years Insulin sensitizers, hepatoprotective agents, antioxidants, lipidlowering agents, drugs induced fatty liver within 1 month</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>